Guru Ownership Trend
Guru Analysis for Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $400,568.
Top institutional holders include Cliff Asness and Steven Cohen.
Institutional sentiment is currently Bullish. This is evidenced by a $384,545 net inflow during the quarter.
Recent activity highlights Cliff Asness who opened a new position.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Inhibikase Therapeutics, Inc. (IKT)
Major holders include Cliff Asness ($288,982), Steven Cohen ($67,843), Renaissance Technologies (RenTech) ($27,720). According to the latest reported data, 3 tracked investment managers collectively hold approximately 228,896 shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $384,545, with 3 managers increasing positions and 0 managers reducing holdings.
No tracked managers reduced or fully exited their positions in IKT during the most recent reporting period.
Yes, 3 managers opened new positions in IKT, and 0 increased their existing holdings. The total reported buy value was $384,545.